Greenland Mines (NASDAQ: GRML) has announced a series of corporate milestones as it transitions into a focused rare earths and critical minerals company, including plans to spin off its biotechnology division in the fourth quarter of 2026. The company also revealed that Nasdaq has formally approved its application related to the March 2026 transaction, resolving prior deficiencies and bringing Greenland Mines into full compliance with listing requirements.
The completion of the acquisition of the Sarfartoq project on Sept. 1, following approval by the Government of Greenland, marks a significant step in the company's strategy. An independent S-K 1300 Initial Assessment for the ST1 deposit estimated a high-case pre-tax net present value of approximately $2.05 billion and a pre-tax internal rate of return of 118.6%. The company highlighted that planned annual neodymium-praseodymium (NdPr) oxide production from ST1 would equal approximately 34% of current NdPr oxide refining outside China based on 2025 consumption levels during each of the project's nine scheduled operating years.
This move underscores the growing importance of rare earth elements, particularly NdPr, which are critical for permanent magnets used in electric vehicles, wind turbines, and other clean energy technologies. By focusing on the Sarfartoq project, Greenland Mines aims to contribute to diversifying the global supply chain for these essential materials, currently dominated by China.
In addition to operational developments, Greenland Mines is reshaping its board. Riad El-Dada and Dr. Shalom Hirschman are stepping down, and capital markets veteran Jason Hawkins is joining the board as the company advances Sarfartoq and its Skaergaard palladium-gold-platinum project. These leadership changes signal a strategic alignment with the company's new focus on mining and critical minerals.
The company's broader vision includes building a multi-asset platform with exposure to rare earth magnet materials, precious metals, and selected midstream processing opportunities, while advancing its North Atlantic Critical Metals Corridor concept linking Greenland resources with allied downstream jurisdictions and industrial infrastructure.
The biotech division, including Klotho's KLTO-202 primary indication for ALS, will be spun off to shareholders, allowing Greenland Mines to streamline its operations and concentrate on its mining assets. This spin-off is expected to unlock value for shareholders by creating two distinct, focused entities.
The announcement comes at a time when global demand for critical minerals is rising, driven by the transition to clean energy and electric mobility. The Sarfartoq project, with its high-grade NdPr deposits, positions Greenland Mines to play a pivotal role in the supply of these materials. The positive initial assessment, with a pre-tax IRR of 118.6%, highlights the project's economic viability and potential to generate significant returns.
Investors and industry observers will be watching closely as Greenland Mines executes its strategic plan. The company's ability to deliver on its milestones, including the successful spin-off and the advancement of the Sarfartoq project, will be key to its future performance. With the support of the Government of Greenland and Nasdaq's approval, Greenland Mines is set to become a notable player in the critical minerals sector.
